155 related articles for article (PubMed ID: 17363527)
1. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients.
Dorn J; Schmitt M; Kates R; Schmalfeldt B; Kiechle M; Scorilas A; Diamandis EP; Harbeck N
Clin Cancer Res; 2007 Mar; 13(6):1742-8. PubMed ID: 17363527
[TBL] [Abstract][Full Text] [Related]
2. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
4. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
5. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
6. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
8. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
10. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Schmalfeldt B; Kuhn W; Reuning U; Pache L; Dettmar P; Schmitt M; Jänicke F; Höfler H; Graeff H
Cancer Res; 1995 Sep; 55(18):3958-63. PubMed ID: 7664262
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma.
Luo LY; Katsaros D; Scorilas A; Fracchioli S; Piccinno R; Rigault de la Longrais IA; Howarth DJ; Diamandis EP
Clin Cancer Res; 2001 Aug; 7(8):2372-9. PubMed ID: 11489815
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
Foekens JA; Ries C; Look MP; Gippner-Steppert C; Klijn JG; Jochum M
Cancer Res; 2003 Jan; 63(2):337-41. PubMed ID: 12543785
[TBL] [Abstract][Full Text] [Related]
15. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker.
Scorilas A; Borgoño CA; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
J Clin Oncol; 2004 Feb; 22(4):678-85. PubMed ID: 14966091
[TBL] [Abstract][Full Text] [Related]
17. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy.
Zheng Y; Katsaros D; Shan SJ; de la Longrais IR; Porpiglia M; Scorilas A; Kim NW; Wolfert RL; Simon I; Li L; Feng Z; Diamandis EP
Clin Cancer Res; 2007 Dec; 13(23):6984-92. PubMed ID: 18056174
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
